Dry Eye
Conditions
Brief summary
The objective of the study is to compare the efficacy and safety of different hyaluronic acid tear substitutes formulations in patients with evaporative dry eye. For this purpose, a randomized, single-blind clinical trial has been designed.
Interventions
DRUGIcross tear substitute
Patients were instructed to instill 1 drop of 0.20% Cross-linked hyaluronic acid substitute into each eye 3 times per day for 3 months.
DRUGHyabak tear substitute
Patients were instructed to instill 1 drop of 0.15% hyaluronic acid substitute into each eye 3 times per day for 3 months.
Sponsors
University of Seville
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Caregiver)
Masking description
0.20% Cross-linked hyaluronic acid tear substitute and 0.15% hyaluronic acid tear substitute are transparent, with no special smell and the bottles were identical in appearance such that patients, investigators and care provider were masked to treatment assignment.
Intervention model description
Patients were instructed to instill 1 drop of 0.20% Cross-linked hyaluronic acid tear substitute or 0.15% hyaluronic acid A tear substitute into each eye 3 times per day for 3 months.
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Self-reported history DED. 2. Ocular surface disease index (OSDI) \> 13 points. 3. Non-invasive tear film break-up time (NIBUT) \< 10 s. 4. Schirmer test (ST) without anesthesia ≥ 5 mm. 5. MGD grade \> 1. For MGD, the Sirius device (CSO, Florence, Italy) was used, which determines MGD grade based on loss area of meibomian glands (LAMG). MGD grade was scored from 0 to 4 (MGD grade 1 = LAMG \< 25%; MGD grade 2 = LAMG ≥ 25% and \< 50%; MGD grade 3 = LAMG ≥ 50% and \< 75%; MGD grade 4 = LAMG ≥ 75%).
Exclusion criteria
1. Abnormal lid anatomy, including active blepharitis, and active lid margin. 2. All corneal disorders that affect diagnostic test, such as active corneal infection and corneal dystrophies. 3. Active ocular allergies. 4. Vectored thermal pulsation (VTP) intense pulse light (IPL), quantum molecular resonance (QMR), or other procedure to treat DED within the previous 6 months. 5. Intraocular surgery or laser ocular surgery within the previous 6 months. 6. Use of topical antibiotics and anti-inflammatory treatments, including steroids and non-steroidal anti-inflammatory drugs. 7. Systemic autoimmune diseases. 8. Contact lens wearers. 9. Pregnant or lactating women. 10. Patients who did not understand or comprehend the informed consent.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Lipid layer thickness (LLT) | This outcome measure was analyzed at baseline, 1 months and 3 months. | The Lipiview® (Johnson & JohsonVision Care, San Francisco, CA, USA) II ocular surface interferometer evaluates LLT automatically assesses LLT with nanometer precision by recording a 20 s video of the tear film interference pattern and then displays the data in interferometric color units (ICU), where1 ICU reflects approximately 1 nm of LLT. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Ocular surface disease index questionnaire | This outcome measure was analyzed at baseline, 1 months and 3 months. | The OSDI questionnaire were employed to assess the severity of DED symptoms, with scores ranging from 0 (indicating no ocular surface disease) to 100 (indicating severe ocular surface disease) points. This questionnaire was provided during consultations at each follow-up visit. |
| Non-invasive tear film break-up time | This outcome measure was analyzed at baseline, 1 months and 3 months. | Tear film stability was automatically assessed using NIBUT by projecting Placido rings from the Sirius device (CSO, Florence, Italy) onto the corneal surface. The time interval between the last blink and the initial distortion of the ring pattern was defined as first NIBUT. This variable was always measured at least 12 hours after administration of the study medication and the average of 3 consecutive measurements was calculated for statistical analysis. |
| Schirmer I test without anesthesia | This outcome measure was analyzed at baseline, 1 months and 3 months. | During the test, the patient is instructed to look upward while the test strip is carefully positioned between the palpebral conjunctiva of the lower eyelid and the bulbar conjunctiva. Subsequently, the patient is asked to keep their eyes gently closed for five minutes. After this period, the test strip is removed, and the Schirmer test score is determined by measuring the length of the moistened area on the strip. |
Countries
Spain
Outcome results
None listed